The molecular regulation of Janus kinase (JAK) activation

Biochemical Journal

Volumn 462, Issue 1, 2014, Pages 1-13

  Babon, Jeffrey J ^a,b   Lucet, Isabelle S ^a,b   Murphy, James M ^a,b   Nicola, Nicos A ^a,b   Varghese, Leila N ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokine receptor; Janus kinase (JAK); Kinase; Pseudokinase

Indexed keywords

CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SH2B3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

DISEASES; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; JAK3 DEFICIENCY; MUTATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD45; ENZYME ACTIVATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MYELOPROLIFERATIVE DISORDERS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTEINS; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TYK2 KINASE;

EID: 84904638434     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140712     Document Type: Review

References (166)

1. Wilks, A. F. (1989) Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 86, 1603-1607 CrossRef PubMed
2. Wilks, A. F., Harpur, A. G., Kurban, R. R., Ralph, S. J., Zürcher, G. and Ziemiecki, A. (1991) Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11, 2057-2065 PubMed (Pubitemid 21895577)
3. Firmbach-Kraft, I., Byers, M., Shows, T., Dalla-Favera, R. and Krolewski, J. J. (1990) Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5, 1329-1336 PubMed
4. Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E. and Ortaldo, J. R. (1994) Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl. Acad. Sci. U.S.A. 91, 6374-6378 CrossRef PubMed (Pubitemid 24200663)
5. Rane, S. G. and Reddy, E. P. (1994) JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 9, 2415-2423 PubMed (Pubitemid 24228695)
6. Velazquez, L., Fellous, M., Stark, G. R. and Pellegrini, S. (1992) A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70, 313-322 CrossRef PubMed
7. Braunstein, J., Brutsaert, S., Olson, R. and Schindler, C. (2003) STATs dimerize in the absence of phosphorylation. J. Biol. Chem. 278, 34133-34140 CrossRef (Pubitemid 37553254)
8. Kretzschmar, A. K., Dinger, M. C., Henze, C., Brocke-Heidrich, K. and Horn, F. (2004) Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem. J. 377, 289-297 CrossRef PubMed (Pubitemid 38142184)
9. Vogt, M., Domoszlai, T., Kleshchanok, D., Lehmann, S., Schmitt, A., Poli, V., Richtering, W. and Muller-Newen, G. (2011) The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. J. Cell Sci. 124, 900-909 CrossRef PubMed
10. Schindler, C., Fu, X. Y., Improta, T., Aebersold, R. and Darnell, Jr, J. E. (1992) Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc. Natl. Acad. Sci. U.S.A. 89, 7836-7839 CrossRef PubMed
11. Schindler, C., Shuai, K., Prezioso, V. R. and Darnell, J. E., Jr. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809-813 CrossRef PubMed
12. Shuai, K., Schindler, C., Prezioso, V. R. and Darnell, Jr, J. E. (1992) Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258, 1808-1812 CrossRef PubMed (Pubitemid 23087351)
13. Dawson, M. A., Bannister, A. J., Gottgens, B., Foster, S. D., Bartke, T., Green, A. R. and Kouzarides, T. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819-822 CrossRef PubMed
14. Lobie, P. E., Ronsin, B., Silvennoinen, O., Haldosen, L. A., Norstedt, G. and Morel, G. (1996) Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology 137, 4037-4045 PubMed (Pubitemid 26284681)
15. Zouein, F. A., Duhe, R. J. and Booz, G. W. (2011) JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors 29, 245-252 CrossRef PubMed
16. Watling, D., Guschin, D., Muller, M., Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Rogers, N. C., Schindler, C., Stark, G. R., Ihle, J. N. et al. (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366, 166-170 CrossRef PubMed
17. Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C. et al. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature 366, 129-135 CrossRef PubMed (Pubitemid 23351817)
18. Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C., Yin, L., Pennica, D. et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373-383 CrossRef PubMed (Pubitemid 28232082)
19. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U. and Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 CrossRef PubMed (Pubitemid 28232084)
20. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M. et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395 CrossRef PubMed (Pubitemid 28232083)
21. Park, S. O., Wamsley, H. L., Bae, K., Hu, Z., Li, X., Choe, S. W., Slayton, W. B., Oh, S. P., Wagner, K. U. and Sayeski, P. P. (2013) Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PloS ONE 8, e59675 CrossRef PubMed
22. Grisouard, J., Hao-Shen, H., Dirnhofer, S., Wagner, K. U. and Skoda, R. C. (2014) Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica 99, e52-e54 CrossRef PubMed
23. Akada, H., Akada, S., Hutchison, R. E., Sakamoto, K., Wagner, K. U. and Mohi, G. (2014) Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells, doi:10.1002/stem.1711
24. Musso, T., Johnston, J. A., Linnekin, D., Varesio, L., Rowe, T. K., O'Shea, J. J. and McVicar, D. W. (1995) Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J. Exp. Med. 181, 1425-1431 CrossRef PubMed
25. Nosaka, T., van Deursen, J. M., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C. and Ihle, J. N. (1995) Defective lymphoid development in mice lacking Jak3. Science 270, 800-802 CrossRef PubMed
26. Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H. and Berg, L. J. (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270, 794-797 CrossRef PubMed
27. Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsall, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T. et al. (1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223-238 CrossRef PubMed
28. DiSanto, J. P., Muller, W., Guy-Grand, D., Fischer, A. and Rajewsky, K. (1995) Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc. Natl. Acad. Sci. U.S.A. 92, 377-381 CrossRef PubMed
29. Noguchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelstein, S., Modi, W. S., McBride, O. W. and Leonard, W. J. (1993) Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157 CrossRef PubMed (Pubitemid 23115456)
30. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G. et al. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549-560 CrossRef PubMed
31. Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T. et al. (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-755 CrossRef PubMed (Pubitemid 46131400)
32. Kilic, S. S., Hacimustafaoglu, M., Boisson-Dupuis, S., Kreins, A. Y., Grant, A. V., Abel, L. and Casanova, J. L. (2012) A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160, 1055-1057 CrossRef PubMed
33. Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F. et al. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751-758 CrossRef (Pubitemid 351549874)
34. Jeong, E. G., Kim, M. S., Nam, H. K., Min, C. K., Lee, S., Chung, Y. J., Yoo, N. J. and Lee, S. H. (2008) Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res. 14, 3716-3721 CrossRef PubMed
35. Pilati, C., Letouze, E., Nault, J. C., Imbeaud, S., Boulai, A., Calderaro, J., Poussin, K., Franconi, A., Couchy, G., Morcrette, G. et al. (2014) Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 25, 428-441 CrossRef PubMed
36. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 CrossRef PubMed (Pubitemid 40386783)
37. James, C., Ugo, V., Le Coúedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 CrossRef PubMed (Pubitemid 40663494)
38. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M. and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 CrossRef PubMed (Pubitemid 40570926)
39. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 CrossRef PubMed (Pubitemid 40544655)
40. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B. and Zhao, Z. J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788-22792 CrossRef PubMed (Pubitemid 40853184)
41. Kratz, C. P., Böll, S., Kontny, U., Schrappe, M., Niemeyer, C. M. and Stanulla, M. (2006) Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20, 381-383 CrossRef PubMed
42. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468 CrossRef PubMed (Pubitemid 46193073)
43. Lee, J. W., Kim, Y. G., Soung, Y. H., Han, K. J., Kim, S. Y., Rhim, H. S., Min, W. S., Nam, S. W., Park, W. S., Lee, J. Y. et al. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25, 1434-1436 CrossRef PubMed (Pubitemid 43336473)
44. Grunebach, F., Bross-Bach, U., Kanz, L. and Brossart, P. (2006) Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20, 2210-2211 CrossRef PubMed (Pubitemid 44782859)
45. Schnittger, S., Bacher, U., Kern, W., Schröder, M., Haferlach, T. and Schoch, C. (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20, 2195-2197 CrossRef PubMed (Pubitemid 44782853)
46. Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G. et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492 CrossRef PubMed
47. Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W. et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 9414-9418 CrossRef PubMed
48. Ma, W., Kantarjian, H., Zhang, X., Yeh, C., Zhang, Z. J., Verstovsek, S. and Albitar, M. (2010) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J. Mol. Diagn. 11, 49-53 CrossRef
49. Passamonti, F., Elena, C., Schnittger, S., Skoda, R., Green, A., Girodon, F., Kiladjian, J., Mcmullin, M., Ruggeri, M., Besses, C. et al. (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117, 2813-2816 CrossRef PubMed
50. Godfrey, A. L. and Green, A. R. (2012) Genotype-phenotype interactions in the myeloproliferative neoplasms. Hematol. Oncol. Clin. North Am. 26, 993-1015 CrossRef PubMed
51. Lacronique, V., Boureux, A., Valle, V. D., Poirel, H., Quang, C. T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J. and Bernard, O. A. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 CrossRef PubMed (Pubitemid 27495745)
52. Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H. and Marynen, P. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540 PubMed (Pubitemid 27413461)
53. Bousquet, M., Quelen, C., De Mas, V., Duchayne, E., Roquefeuil, B., Delsol, G., Laurent, G., Dastugue, N. and Brousset, P. (2005) The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24, 7248-7252 CrossRef PubMed (Pubitemid 41679286)
54. Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J. A. et al. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 65, 2662-2667 CrossRef PubMed (Pubitemid 40490065)
55. Griesinger, F., Hennig, H., Hillmer, F., Podleschny, M., Steffens, R., Pies, A., Wormann, B., Haase, D. and Bohlander, S. K. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44, 329-333 CrossRef PubMed (Pubitemid 41397102)
56. O'Shea, J. J., Husa, M., Li, D., Hofmann, S. R., Watford, W., Roberts, J. L., Buckley, R. H., Changelian, P. and Candotti, F. (2004) Jak3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. 41, 727-737 CrossRef PubMed (Pubitemid 38824626)
57. Walters, D. K., Mercher, T., Gu, T. L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J. et al. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75 CrossRef PubMed
58. Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S. et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117-1127 CrossRef PubMed
59. Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787-798 CrossRef PubMed
60. Zhang, X., Liang, F., Yin, X., Xiao, X., Shi, P., Wei, D., Yao, L., Wang, Q. and Chen, Y. (2014) Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis. Clin. Rheumatol. 33, 165-173 CrossRef PubMed
61. Wallweber, H. J., Tam, C., Franke, Y., Starovasnik, M. A. and Lupardus, P. J. (2014) Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21, 443-448 CrossRef PubMed
62. Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395 CrossRef PubMed (Pubitemid 30243884)
63. Saharinen, P. and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963 CrossRef PubMed (Pubitemid 36159324)
64. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C. F., Neubert, T. A., Skoda, R. C., Hubbard, S. R. and Silvennoinen, O. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976 CrossRef PubMed
65. Feng, J., Witthuhn, B. A., Matsuda, T., Kohlhuber, F., Kerr, I. M. and Ihle, J. N. (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17, 2497-2501 PubMed (Pubitemid 27175130)
66. Chatti, K., Farrar, W. L. and Duhé, R. J. (2004) Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43, 4272-4283 CrossRef PubMed (Pubitemid 38445648)
67. Toms, A. V., Deshpande, A., McNally, R., Jeong, Y., Rogers, J. M., Kim, C. U., Gruner, S. M., Ficarro, S. B., Marto, J. A., Sattler, M. et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221-1223 CrossRef PubMed
68. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O. and Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759 CrossRef PubMed
69. Murphy, J. M., Zhang, Q., Young, S. N., Reese, M. L., Bailey, F. P., Eyers, P. A., Ungureanu, D., Hammaren, H., Silvennoinen, O., Varghese, L. N. et al. (2014) A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem. J. 457, 323-334 CrossRef PubMed
70. Murphy, J. M., Czabotar, P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J. G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I. et al. (2013) The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443-453 CrossRef PubMed
71. Dusa, A., Mouton, C., Pecquet, C., Herman, M. and Constantinescu, S. N. (2010) JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PloS ONE 5, e11157 CrossRef PubMed
72. Zhao, L., Dong, H., Zhang, C., Kinch, L., Osawa, M., Iacovino, M., Grishin, N., Kyba, M. and Huang, L. (2009) A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J. Biol. Chem. 284, 26988-26998 CrossRef PubMed
73. Lu, X., Huang, L. J. and Lodish, H. F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266 CrossRef PubMed
74. Wernig, G., Gonneville, J. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., Hudon, H. E., Walz, C., Reiter, A., Podar, K., Royer, Y. et al. (2008) The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111, 3751-3759 CrossRef PubMed
75. Gorantla, S. P., Dechow, T. N., Grundler, R., Illert, A. L., Zum Büschenfelde, C. M., Kremer, M., Peschel, C. and Duyster, J. (2010) Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. Blood 116, 4600-4611 CrossRef PubMed
76. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R. and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030 CrossRef PubMed
77. Varghese, L. N., Ungureanu, D., Liau, N. P., Young, S. N., Laktyushin, A., Hammaren, H., Lucet, I. S., Nicola, N. A., Silvennoinen, O., Babon, J. J. and Murphy, J. M. (2014) Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem. J. 458, 395-405 CrossRef PubMed
78. Lupardus, P. J., Skiniotis, G., Rice, A. J., Thomas, C., Fischer, S., Walz, T. and Garcia, K. C. (2011) Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 19, 45-55 CrossRef PubMed
79. Brooks, A. J., Dai, W., O'Mara, M. L., Abankwa, D., Chhabra, Y., Pelekanos, R. A., Gardon, O., Tunny, K. A., Blucher, K. M., Morton, C. J. et al. (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344, 1249783 CrossRef PubMed
80. Lee, T. S. (2013) On the regulation and activation of JAK2: a novel hypothetical model. Mol. Cancer Res. 11, 811-814 CrossRef PubMed
81. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O. et al. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159 CrossRef PubMed
82. Wallweber, H. J., Tam, C., Franke, Y., Starovasnik, M. A. and Lupardus, P. J. (2014) Structural basis of recognition of interferon-α receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21, 443-448 CrossRef PubMed
83. Shultz, L. D., Rajan, T. V. and Greiner, D. L. (1997) Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 15, 302-307 CrossRef PubMed (Pubitemid 27330625)
84. David, M., Chen, H. E., Goelz, S., Larner, A. C. and Neel, B. G. (1995) Differential regulation of the α/β interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15, 7050-7058
85. Yetter, A., Uddin, S., Krolewski, J. J., Jiao, H., Yi, T. and Platanias, L. C. (1995) Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J. Biol. Chem. 270, 18179-18182 CrossRef PubMed
86. Jiao, H., Berrada, K., Yang, W., Tabrizi, M., Platanias, L. C. and Yi, T. (1996) Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 16, 6985-6992 PubMed (Pubitemid 26389758)
87. Bone, H., Dechert, U., Jirik, F., Schrader, J. W. and Welham, M. J. (1997) SHP1 and SHP2 protein-tyrosine phosphatases associate with betac after interleukin-3-induced receptor tyrosine phosphorylation. Identification of potential binding sites and substrates. J. Biol. Chem. 272, 14470-14476 CrossRef PubMed (Pubitemid 27232868)
88. Tauchi, T., Damen, J. E., Toyama, K., Feng, G. S., Broxmeyer, H. E. and Krystal, G. (1996) Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood 87, 4495-4501 PubMed (Pubitemid 26162354)
89. Alicea-Velazquez, N. L., Jakoncic, J. and Boggon, T. J. (2013) Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition. J. Struct. Biol. 181, 243-251 CrossRef PubMed
90. Chim, C. S., Kwong, Y. L., Fung, T. K. and Liang, R. (2004) SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103, 4630-4635 CrossRef PubMed
91. Chim, C. S., Wong, K. Y., Loong, F. and Srivastava, G. (2004) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18, 356-358 CrossRef PubMed (Pubitemid 38240055)
92. Yin, T., Shen, R., Feng, G. S. and Yang, Y. C. (1997) Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases. J. Biol. Chem. 272, 1032-1037 CrossRef PubMed (Pubitemid 27034597)
93. You, M., Yu, D. H. and Feng, G. S. (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19, 2416-2424 PubMed (Pubitemid 29098299)
94. Chan, R. J. and Feng, G. S. (2007) PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867 CrossRef PubMed (Pubitemid 46220628)
95. Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S. et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 CrossRef PubMed (Pubitemid 34326699)
96. Zabolotny, J. M., Bence-Hanulec, K. K., Stricker-Krongrad, A., Haj, F., Wang, Y., Minokoshi, Y., Kim, Y. B., Elmquist, J. K., Tartaglia, L. A., Kahn, B. B. and Neel, B. G. (2002) PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2, 489-495 CrossRef PubMed (Pubitemid 34436576)
97. Lund, I. K., Hansen, J. A., Andersen, H. S., Moller, N. P. H. and Billestrup, N. (2005) Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J. Mol. Endocrinol. 34, 339-351 CrossRef (Pubitemid 40585186)
98. Myers, M. P., Andersen, J. N., Cheng, A., Tremblay, M. L., Horvath, C. M., Parisien, J. P., Salmeen, A., Barford, D. and Tonks, N. K. (2001) TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276, 47771-47774 CrossRef PubMed
99. Cheng, A., Uetani, N., Simoncic, P. D., Chaubey, V. P., Lee-Loy, A., McGlade, C. J., Kennedy, B. P. and Tremblay, M. L. (2002) Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2, 497-503 CrossRef PubMed (Pubitemid 34436577)
100. Johnson, K. J., Peck, A. R., Liu, C., Tran, T. H., Utama, F. E., Sjolund, A. B., Schaber, J. D., Witkiewicz, A. K. and Rui, H. (2010) PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am. J. Pathol. 177, 2971-2983 CrossRef PubMed
101. Simoncic, P. D., Lee-Loy, A., Barber, D. L., Tremblay, M. L. and McGlade, C. J. (2002) The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 12, 446-453 CrossRef PubMed
102. Kleppe, M., Lahortiga, I., El Chaar, T., De Keersmaecker, K., Mentens, N., Graux, C., Van Roosbroeck, K., Ferrando, A. A. and Langerak, A. W. (2010) Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, U530-U584 CrossRef
103. Kleppe, M., Soulier, J., Asnafi, V., Mentens, N., Hornakova, T., Knoops, L., Constantinescu, S., Sigaux, F., Meijerink, J. P., Vandenberghe, P. et al. (2011) PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 117, 7090-7098 CrossRef PubMed
104. Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., Griffiths, E., Krawczyk, C., Richardson, C. D., Aitken, K. et al. (2001) CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349-354 CrossRef PubMed (Pubitemid 32151240)
105. Porcu, M., Kleppe, M., Gianfelici, V., Geerdens, E., De Keersmaecker, K., Tartaglia, M., Foa, R., Soulier, J., Cauwelier, B., Uyttebroeck, A. et al. (2012) Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 119, 4476-4479 CrossRef PubMed
106. Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H. et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924 CrossRef PubMed (Pubitemid 27289595)
107. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A. and Hilton, D. J. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921 CrossRef PubMed (Pubitemid 27289594)
108. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K. et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929 CrossRef PubMed (Pubitemid 27289596)
109. Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D. and Nicola, N. A. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U.S.A. 95, 114-119 CrossRef PubMed (Pubitemid 28103916)
110. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N. and Yoshimura, A. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320 CrossRef PubMed (Pubitemid 29110315)
111. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A. and Yoshimura, A. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339-351 CrossRef PubMed (Pubitemid 29359449)
112. Babon, J. J., Yao, S., DeSouza, D. P., Harrison, C. F., Fabri, L. J., Liepinsh, E., Scrofani, S. D., Baca, M. and Norton, R. S. (2005) Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J. 272, 6120-6130 CrossRef PubMed (Pubitemid 41713701)
113. Babon, J. J., McManus, E. J., Yao, S., DeSouza, D. P., Mielke, L. A., Sprigg, N. S., Willson, T. A., Hilton, D. J., Nicola, N. A., Baca, M. et al. (2006) The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol. Cell 22, 205-216 CrossRef PubMed (Pubitemid 44316440)
114. Kershaw, N. J., Murphy, J. M., Liau, N. P., Varghese, L. N., Laktyushin, A., Whitlock, E. L., Lucet, I. S., Nicola, N. A. and Babon, J. J. (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20, 469-476 CrossRef PubMed
115. Babon, J. J., Kershaw, N. J., Murphy, J. M., Varghese, L. N., Laktyushin, A., Young, S. N., Lucet, I. S., Norton, R. S. and Nicola, N. A. (2012) Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250 CrossRef PubMed
116. Roberts, A. W., Robb, L., Rakar, S., Hartley, L., Cluse, L., Nicola, N. A., Metcalf, D., Hilton, D. J. and Alexander, W. S. (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. U.S.A. 98, 9324-9329 CrossRef PubMed (Pubitemid 32743915)
117. Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira, S., Hoshijima, M. et al. (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4, 551-556 CrossRef PubMed (Pubitemid 36701338)
118. Kinjyo, I., Inoue, H., Hamano, S., Fukuyama, S., Yoshimura, T., Koga, K., Takaki, H., Himeno, K., Takaesu, G., Kobayashi, T. and Yoshimura, A. (2006) Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-â 1. J. Exp. Med. 203, 1021-1031 CrossRef PubMed
119. Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T. and Yoshimura, A. (2006) Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene
120. Croker, B. A., Krebs, D. L., Zhang, J. G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Forster, I., Clausen, B. E. et al. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 CrossRef PubMed (Pubitemid 36701336)
121. Croker, B. A., Metcalf, D., Robb, L., Wei, W., Mifsud, S., DiRago, L., Cluse, L. A., Sutherland, K. D., Hartley, L., Williams, E. et al. (2004) SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20, 153-165 CrossRef PubMed (Pubitemid 38258392)
122. Mori, H., Hanada, R., Hanada, T., Aki, D., Mashima, R., Nishinakamura, H., Torisu, T., Chien, K. R., Yasukawa, H. and Yoshimura, A. (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat. Med. 10, 739-743 CrossRef PubMed (Pubitemid 38937640)
123. Babon, J. J. and Nicola, N. A. (2012) The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 30, 207-219 CrossRef PubMed
124. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M. et al. (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 CrossRef PubMed (Pubitemid 29418951)
125. Bullen, D. V., Darwiche, R., Metcalf, D., Handman, E. and Alexander, W. S. (2001) Neutralization of interferon-γ in neonatal SOCS1 -/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease. Immunology 104, 92-98 CrossRef PubMed
126. Sporri, B., Kovanen, P. E., Sasaki, A., Yoshimura, A. and Leonard, W. J. (2001) JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 97, 221-226 CrossRef PubMed (Pubitemid 32061264)
127. Huang, X., Li, Y., Tanaka, K., Moore, K. G. and Hayashi, J. I. (1995) Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 92, 11618-11622 CrossRef PubMed (Pubitemid 26014164)
128. Liu, B. A., Jablonowski, K., Raina, M., Arce, M., Pawson, T. and Nash, P. D. (2006) The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol. Cell 22, 851-868 CrossRef PubMed
129. Kurzer, J. H., Saharinen, P., Silvennoinen, O. and Carter-Su, C. (2006) Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol. Cell. Biol. 26, 6381-6394 CrossRef PubMed (Pubitemid 44277879)
130. O'Brien, K. B., O'Shea, J. J. and Carter-Su, C. (2002) SH2-B family members differentially regulate JAK family tyrosine kinases. J. Biol. Chem. 277, 8673-8681 CrossRef PubMed (Pubitemid 34968334)
131. Takaki, S., Sauer, K., Iritani, B. M., Chien, S., Ebihara, Y., Tsuji, K., Takatsu, K. and Perlmutter, R. M. (2000) Control of B cell production by the adaptor protein lnk. Definition Of a conserved family of signal-modulating proteins. Immunity 13, 599-609 CrossRef PubMed
132. Velazquez, L., Cheng, A. M., Fleming, H. E., Furlonger, C., Vesely, S., Bernstein, A., Paige, C. J. and Pawson, T. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med. 195, 1599-1611 CrossRef PubMed (Pubitemid 34666073)
133. Ema, H., Sudo, K., Seita, J., Matsubara, A., Morita, Y., Osawa, M., Takatsu, K., Takaki, S. and Nakauchi, H. (2005) Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev. Cell 8, 907-914 CrossRef PubMed (Pubitemid 40754061)
134. Tong, W., Zhang, J. and Lodish, H. F. (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105, 4604-4612 CrossRef PubMed (Pubitemid 40807278)
135. Buza-Vidas, N., Antonchuk, J., Qian, H., Mansson, R., Luc, S., Zandi, S., Anderson, K., Takaki, S., Nygren, J. M., Jensen, C. T. and Jacobsen, S. E. (2006) Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 20, 2018-2023 CrossRef PubMed (Pubitemid 44157453)
136. Seita, J., Ema, H., Ooehara, J., Yamazaki, S., Tadokoro, Y., Yamasaki, A., Eto, K., Takaki, S., Takatsu, K. and Nakauchi, H. (2007) Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc. Natl. Acad. Sci. U.S.A. 104, 2349-2354 CrossRef PubMed (Pubitemid 46391400)
137. Baran-Marszak, F., Magdoud, H., Desterke, C., Alvarado, A., Roger, C., Harel, S., Mazoyer, E., Cassinat, B., Chevret, S., Tonetti, C. et al. (2010) Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 116, 5961-5971 CrossRef PubMed
138. Tong, W. and Lodish, H. F. (2004) Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med. 200, 569-580 CrossRef PubMed (Pubitemid 39258306)
139. Bersenev, A., Wu, C., Balcerek, J. and Tong, W. (2008) Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest. 118, 2832-2844 PubMed
140. Louria-Hayon, I., Frelin, C., Ruston, J., Gish, G., Jin, J., Kofler, M. M., Lambert, J. P., Adissu, H. A., Milyavsky, M., Herrington, R. et al. (2013) Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling. Proc. Natl. Acad. Sci. U.S.A. 110, 20599-20604 CrossRef PubMed
141. Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, Jr, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P. and Gotlib, J. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116, 988-992 CrossRef PubMed
142. Zhang, J. H., Mullighan, C. G., Harvey, R. C., Wu, G., Chen, X., Edmonson, M., Buetow, K. H., Carroll, W. L., Chen, I. M., Devidas, M. et al. (2011) Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080-3087 CrossRef PubMed
143. Loh, M. L., Zhang, J., Harvey, R. C., Roberts, K., Payne-Turner, D., Kang, H., Wu, G., Chen, X., Becksfort, J., Edmonson, M. et al. (2013) Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 121, 485-488 CrossRef PubMed
144. Matsuda, T., Feng, J., Witthuhn, B. A., Sekine, Y. and Ihle, J. N. (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochem. Biophys. Res. Commun. 325, 586-594 CrossRef (Pubitemid 39458035)
145. Godeny, M. D., Sayyah, J., VonDerLinden, D., Johns, M., Ostrov, D. A., Caldwell-Busby, J. and Sayeski, P. P. (2007) The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cell. Signal. 19, 600-609 CrossRef PubMed (Pubitemid 46107811)
146. Feener, E. P., Rosario, F., Dunn, S. L., Stancheva, Z. and Myers, M. G. (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978 CrossRef PubMed (Pubitemid 38668060)
147. Argetsinger, L. S., Kouadio, J. L., Steen, H., Stensballe, A., Jensen, O. N. and Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967 CrossRef PubMed (Pubitemid 38668059)
148. Robertson, S. A., Koleva, R. I., Argetsinger, L. S., Carter-Su, C., Marto, J. A., Feener, E. P. and Myers, Jr, M. G. (2009) Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol. Cell. Biol. 29, 3367-3378 CrossRef PubMed
149. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y. et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 CrossRef PubMed (Pubitemid 350235027)
150. Kurzer, J. H., Argetsinger, L. S., Zhou, Y. J., Kouadio, J. L., O'Shea, J. J. and Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ. Mol. Cell. Biol. 24, 4557-4570 CrossRef PubMed (Pubitemid 44109138)
151. Ishida-Takahashi, R., Rosario, F., Gong, Y., Kopp, K., Stancheva, Z., Chen, X., Feener, E. P. and Myers, Jr, M. G. (2006) Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26, 4063-4073 CrossRef PubMed (Pubitemid 43788010)
152. Mazurkiewicz-Munoz, A. M., Argetsinger, L. S., Kouadio, J. L., Stensballe, A., Jensen, O. N., Cline, J. M. and Carter-Su, C. (2006) Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26, 4052-4062 CrossRef PubMed (Pubitemid 43788009)
153. Sedek, M. and Strous, G. J. (2013) SUMOylation is a regulator of the translocation of Jak2 between nucleus and cytosol. Biochem. J. 453, 231-239 CrossRef PubMed
154. Funakoshi-Tago, M., Pelletier, S., Matsuda, T., Parganas, E. and Ihle, J. N. (2006) Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 25, 4763-4772 CrossRef PubMed (Pubitemid 44607022)
155. Funakoshi-Tago, M., Tago, K., Kasahara, T., Parganas, E. and Ihle, J. N. (2008) Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cell. Signal. 20, 1995-2001 CrossRef PubMed
156. Argetsinger, L. S., Stuckey, J. A., Robertson, S. A., Koleva, R. I., Cline, J. M., Marto, J. A., Myers, Jr, M. G. and Carter-Su, C. (2010) Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol. Endocrinol. 24, 1062-1076 CrossRef PubMed
157. Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F. and Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 CrossRef PubMed (Pubitemid 43053540)
158. Krempler, A., Qi, Y., Triplett, A. A., Zhu, J., Rui, H. and Wagner, K. U. (2004) Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 40, 52-57 CrossRef PubMed (Pubitemid 39655118)
159. Wagner, K. U., Krempler, A., Triplett, A. A., Qi, Y., George, N. M., Zhu, J. and Rui, H. (2004) Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell. Biol. 24, 5510-5520 CrossRef PubMed (Pubitemid 38738182)
160. Park, S. Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T. and Saito, T. (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3, 771-782 CrossRef PubMed (Pubitemid 26091150)
161. Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Shea, J. J. et al. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68 CrossRef PubMed
162. Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T. S., Noguchi, M., Markert, M. L., Buckley, R. H. et al. (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 CrossRef PubMed
163. Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., Yamashita, M., Numata, A., Takase, K., Kobayashi, S. et al. (2000) Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561-571 CrossRef PubMed
164. Karaghiosoff, M., Steinborn, R., Kovarik, P., Kriegshauser, G., Baccarini, M., Donabauer, B., Reichart, U., Kolbe, T., Bogdan, C., Leanderson, T. et al. (2003) Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4, 471-477 CrossRef PubMed (Pubitemid 36592440)
165. Shaw, M. H., Boyartchuk, V., Wong, S., Karaghiosoff, M., Ragimbeau, J., Pellegrini, S., Muller, M., Dietrich, W. F. and Yap, G. S. (2003) A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. U.S.A 100, 11594-11599 CrossRef PubMed (Pubitemid 37205981)
166. Vielnascher, R. M., Hainzl, E., Leitner, N. R., Rammerstorfer, M., Popp, D., Witalisz, A., Rom, R., Karaghiosoff, M., Kolbe, T., Muller, S. et al. (2014) Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res. 23, 519-529 CrossRef PubMed